Patients’ and professionals’ views related to ethical issues in precision medicine: a mixed research synthesis
Open accessThe DOI matches its Crossref record; 128 of the 130 references it cites were found in a registry or an index; 105 of the 236 sources its claims cite were checked for support.
Abstract
Background Precision medicine development is driven by the possibilities of next generation sequencing, information technology and artificial intelligence and thus, raises a number of ethical questions.
Overview
CoChat Summary
TL;DR
This mixed research synthesis of 92 empirical studies finds that patients and professionals generally expect high benefits from precision medicine but share ethical concerns about evidence, informed consent, access, data misuse, discrimination, incidental findings, the doctor-patient relationship, and pressure to self-optimize. It concludes that justice, autonomy, nonmaleficence, and further research on cost-effectiveness and quality of life require more attention.
Key findings
- The review included 92 publications: 62 studies investigated professionals’ perceptions and 45 reported patients’ views; 13 ethically relevant topics were identified and mapped to Beauchamp and Childress’ principles of beneficence, nonmaleficence, autonomy, and justice.
- Commonly perceived risks included lack of evidence for test accuracy and treatment efficacy; limited patient knowledge complicating informed consent; possible unavailability of access for underprivileged people and ethnic minorities; misuse of data by insurance companies and employers; racial stigmatization from genetic information; unwanted incidental findings; changes in the doctor-patient relationship through focusing on data; and pressure on patients to optimize their health.
- Reported numbers include: 85% of patients felt well informed after their doctor’s explanation versus 23% of doctors agreeing patients were well informed; 84.8% of Korean participants (n = 542) were concerned PM would increase public health disparity; 27.8% of Saudi physicians (n = 126) doubted easy patient access; 78% of US patients, HCPs, and patient representatives (n = 72) were concerned about difficulty helping patients gain access; only 38.5% of US doctors (n = 104) believed PM was available to all ethnic groups; and 82.5% of 126 South Arabian physicians had poor knowledge of PM in diabetes management.
- Patients and professionals were generally positive about PM, and patients showed high willingness to donate data and biospecimens, though fewer supported smartphone apps for lifestyle tracking; concerns included high costs, insurance coverage, and compensation if pharmaceutical companies profit from patient donations.
Methods
- Mixed Research Synthesis integrating quantitative and qualitative studies, mainly using a qualitizing approach; a systematic search in five databases yielded 1004 records, reduced to 665 after duplicates, then 141 full-texts screened, 49 excluded, and 92 publications included.
- Inclusion criteria covered empirical studies and reviews on patients’ and professionals’ expectations, concerns, values, and attitudes toward PM; patients were people with diseases or disabilities or patient-organization representatives, and professionals were physicians, other HCPs, and researchers; languages were German and English, with no year limit and worldwide origin.
- Data were extracted into a spreadsheet, themes were identified and assigned to 13 topics related to Beauchamp and Childress’ four principles, and findings were summarized and discussed iteratively.
Limitations
- Stated: the search strategy was limited to three title terms—precision medicine, personalized medicine, and genomic medicine—omitting individualized medicine and systems medicine, which likely missed relevant studies.
- Stated: screening and eligibility assessment were performed by only one researcher; a second person would have increased reliability.
- Evident in the text: included studies are heavily concentrated in oncology, which may limit the generalizability of the synthesized perspectives to other medical fields.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
67 Valid · 5 Not valid · 47 Not checked · 38 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Various studies reveal that the majority of professionals have a positive attitude towards PM in general or towards interventions, which are mentioned under the label of PM [27, 34, 43, 45, 47, 50, 79–83].”
§ Patients’ and professionals’ views related to ethical issues in precision medicine: a mixed research synthesis > Results > Benefits of precision medicine
What the sources say
- Supportedcites [27] Bonter K, Desjardins C, Currier N, Pun J, Ashbury FD. Personalised medicine in Canada: a survey of adoption and practice in oncology, cardiology and family medicine. BMJ Open. 2011;1(1):e000110. source
The Discussion (Attitudes, impacts and benefits; page not supplied) says Canadian physicians responding to the survey were optimistic about personalised medicine and open to its use. It reports that majorities believed genetic testing as a component of personalised medicine could influence treatment plans (83%) and improve outcomes (70%). (LLM, conf=0.91)
- Supportedcites [34] Dion-Labrie M, Fortin MC, Hebert MJ, Doucet H. The use of personalized medicine for patient selection for renal transplantation: physicians’ views on the clinical and ethical implications. BMC Med Ethics. 2010;11:5. source
The Conclusions state that a majority of the participating physicians favoured the personalized-medicine approach studied for renal transplantation. This supports the citing sentence’s intervention-specific alternative, not a claim about professionals’ attitudes toward precision medicine in general. (LLM, conf=0.91)
- Partly supportedcites [43] Malentacchi F, Mancini I, Brandslund I, Vermeersch P, Schwab M, Marc J, et al. Is laboratory medicine ready for the era of personalized medicine? A survey addressed to laboratory directors of hospitals/academic schools of medicine in Europe. Clin Chem Lab Med. 2015;53(7):981–8. sourceExperimental — accuracy not yet measured
The survey supports a majority positive stance, but only within its own sample: Questionnaire part 1 (question 6) states that 'the majority of laboratories agreed about the importance of this new discipline to improve the European patients' conditions', the 87% majority on question 7 (cooperation/collaboration to consolidate a PM approach), and the Abstract/Conclusions say the participating laboratory medicine professionals see PM as 'a new and promising health model' and are 'willing and able to participate actively in this evolution'. That covers professionals in laboratory medicine in Europe, not 'professionals' in general as the citing sentence asserts, and the paper reports agreement on the importance of PM as a discipline rather than attitudes toward specific interventions labelled as PM. The second limb of the claim ('interventions mentioned under the label of PM') is therefore not attributable to this source. (LLM, conf=0.72)
- Not checked — no full text of the sourcecites [45] Schwartz EJ, Issa AM. The role of hospital pharmacists in the adoption and use of pharmacogenomics and precision medicine. Per Med. 2017;14(1):27–35. source
- Supportedcites [47] Cho H, Shin SY, Hwangbo B, Chang YJ, Cho J, Kong SY, et al. Views on precision medicine among health professionals in korea: a mixed methods study. Yonsei Med J. 2020;61(2):192–7. source
The study reports positive attitudes toward precision medicine among the surveyed health professionals in Korea: about 95–96% expected it to improve treatment and diagnosis. This supports the cited paper as one example behind the sentence’s statement about a majority of professionals. (LLM, conf=0.93)
- Not checked — no full text of the sourcecites [50] Suther SG, Goodson P. Texas physicians’ perceptions of genomic medicine as an innovation. Clin Genet. 2004;65(5):368–77. source
- Partly supportedcites [79] Di Paolo A, Sarkozy F, Ryll B, Siebert U. Personalized medicine in Europe: not yet personal enough? BMC Health Serv Res. 2017;17:9. sourceExperimental — accuracy not yet measured
The Expert interviews section reports that 70% of experts who answered a question about patient segmentation associated it with improved outcomes, and 55% with better side-effect profiles. This supports a favorable view of potential benefits, but the paper does not establish that a majority of professionals had a positive attitude toward precision medicine generally or toward interventions labeled as such. (LLM, conf=0.78)
- Not checked — no full text of the sourcecites [80] Gingras I, Sonnenblick A, Dolci S, de Azambuja E, Paesmans M, Delaloge S, et al. The role of precision medicine in “real-life” management of breast cancer patients: a survey assessing the current use and attitudes towards tumor molecular sequencing in clinical practice. Cancer Res. 2016;76:2. source
- Supportedcites [81] Obeng AO, Fei KZ, Levy KD, Elsey AR, Pollin TI, Ramirez AH, et al. Physician-reported benefits and barriers to clinical implementation of genomic medicine: a multi-site IGNITE-network survey. J Pers Med. 2018;8(3):13. source
The Results (§4.3; page not provided) report that two thirds of surveyed physicians considered genetic or pharmacogenetic testing relevant to their clinical practice. The Abstract identifies genetic medicine as a component of personalized medicine and says the majority believed genetic testing was clinically useful. This supports the claim for an intervention under the precision-medicine label, rather than for precision medicine in general. (LLM, conf=0.89)
- Supportedcites [82] Alharbi AA, Shaqran TM, Eltobgy AAE, Albalawi AR, Alnawmasi WS. Physicians’ perspective on diabetes mellitus management within the context of personalized medicine Era in Tabuk Governorate, Saudi Arabia. Open Access Maced J Med Sci. 2019;7(10):1706–11. source
The Results (Table 3) report that 72 of 126 physicians (57.1%) had favourable overall attitudes toward personalized diabetes management. This supports the citing sentence’s characterization of this study as finding a majority positive toward an intervention under the personalized-medicine label. (LLM, conf=0.91)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“However, as other studies have demonstrated, many patients generally have a limited knowledge about PM [65, 71, 99–102], genetic testing [62, 69, 95] and pharmacogenomics [73, 101] and also express difficulties in understanding [51].”
§ Patients’ and professionals’ views related to ethical issues in precision medicine: a mixed research synthesis > Results > Patients’ understanding and knowledge
What the sources say
- Not checked — no full text of the sourcecites [65] Howe R, Miron-Shatz T, Hanoch Y, Omer Z, O’Donoghue C, Ozanne E. Personalized medicine through SNP testing for breast cancer risk: clinical implementation. J Genet Couns. 2015;24(5):744–51. source
- Not checked — no full text of the sourcecites [71] Choukour M, Kivits J, Baker A, Baumann C, Guillemin F, Peyrin-Biroulet L. Personalised medicine in inflammatory bowel diseases: a patient survey. Scand J Gastroenterol. 2019;54(1):135. source
- Not checked yetcites [99] Giusti K, Young AQ, Winget M, Lehrhaupt K. Understanding differences in critical decisions in the multiple myeloma patient journey in the era of precision medicine. Am J Hematol-Oncol. 2017;13(3):26–37.
- Not checked yetcites [100] McFarland DC, Hamilton JG, Fox R, Holland J. Putting the “person” in personalized cancer medicine: a systematic review of psychological aspects of targeted therapy. Pers Med Oncol. 2014;3(8):438–47.
Checked before — its earlier verdict is held back until a new check runs.
- Supportedcites [101] Williams JR, Yeh VM, Bruce MA, Szetela C, Ukoli F, Wilkins CH, et al. Precision medicine: familiarity, perceived health drivers, and genetic testing considerations across health literacy levels in a diverse sample. J Genet Couns. 2019;28(1):59–69. source
The Results section, “Familiarity with precision medicine terms” (page not provided), reports that only 23.8% of participants were moderately or extremely familiar with “precision medicine” and 19.0% were familiar with “pharmacogenomics.” The cited paper thus supports the limited-familiarity point for those two topics. The citing sentence attaches a separate set of citations to genetic testing. (LLM, conf=0.88)
- Not checked — no full text of the sourcecites [102] McCarty CA, Nair A, Austin DM, Giampietro PF. Informed consent and subject motivation to participate in a large, population-based genomics study: the Marshfield Clinic Personalized Medicine Research Project. Community Genet. 2007;10(1):2–9. source
- Not checked — no full text of the sourcecites [62] Giusti K, Young AQ, Lehrhaupt K. Closing knowledge gaps to optimize patient outcomes and advance precision medicine. Cancer J. 2018;24(3):144–51. source
- Not matchedcites [69] Sommer M, Nielsen MM, Vesteghem C, Bogsted M, Dybkjaer K, Johnsen HE, et al. Hämatological cancer patients’ position on precision medicine—a questionnaire survey. Basic Clin Pharmacol Toxicol. 2018;123:4.
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Not checked — no full text of the sourcecites [95] De Marco M, Cykert S, Coad N, Doost K, Schaal J, White B, et al. Views on personalized medicine: do the attitudes of African American and white prescription drug consumers differ? Pub Health Genom. 2010;13(5):276–83. source
- Not checked — no full text of the sourcecites [73] Issa AM, Tufail W, Hutchinson J, Tenorio J, Baliga MP. Assessing patient readiness for the clinical adoption of personalized medicine. Pub Health Genom. 2009;12(3):163–9. source
boosted- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Apart from these positive assessments, studies also demonstrate that some professionals are uncertain about the value of genetic testing [51, 90] and doubt that all patients will benefit significantly from PM [30, 31, 42, 49, 54, 57].”
§ Patients’ and professionals’ views related to ethical issues in precision medicine: a mixed research synthesis > Results > Benefits of precision medicine
What the sources say
- Not checked — no full text of the sourcecites [30] McCarthy MC, De Abreu LR, McMillan LJ, Meshcheriakova E, Cao A, Gillam L. Finding out what matters in decision-making related to genomics and personalized medicine in pediatric oncology: developing attributes to include in a discrete choice experiment. Patient. 2020. https://doi.org/10.1007/s40271-020-00411-0. source
- Not checked yetcites [31] McGill BC, Wakefield CE, Hetherington K, Munro LJ, Warby M, Lau L, et al. “Balancing expectations with actual realities”: conversations with clinicians and scientists in the first year of a high-risk childhood cancer precision medicine trial. J Pers Med. 2020. https://doi.org/10.3390/jpm10010009(9). doi:10.3390/jpm10010009(9
- Partly supportedcites [42] Ormondroyd E, Mackley MP, Blair E, Craft J, Knight JC, Taylor JC, et al. “Not pathogenic until proven otherwise”: perspectives of UK clinical genomics professionals toward secondary findings in context of a Genomic Medicine Multidisciplinary Team and the 100,000 Genomes Project. Genet Med. 2018;20(3):320–8. sourceExperimental — accuracy not yet measured
The Abstract’s Results (page unavailable) report that some professionals questioned genome screening because evidence of clinical utility was lacking. The Results on informed consent also say some thought participants overestimated the yield and value of secondary findings. These concerns support doubt about benefit in that specific setting, but not the broader claim about whether all patients benefit significantly from precision medicine. (LLM, conf=0.85)
- Not checked — no full text of the sourcecites [49] Carroll JC, Makuwaza T, Manca DP, Sopcak N, Permaul JA, O’Brien MA, et al. Primary care providers’ experiences with and perceptions of personalized genomic medicine. Can Fam Physician. 2016;62(10):e626–35.
- Supportedcites [54] Schleidgen S, Marckmann G. Re-focusing the ethical discourse on personalized medicine: a qualitative interview study with stakeholders in the German healthcare system. BMC Med Ethics. 2013;14(1):20. source
In Results > Current state of PM (page not provided), the authors report that some stakeholders considered the added therapeutic benefit of personalized measures small compared with standard interventions. A respondent says that, in many cases, modern cancer therapies differ from classical chemotherapy by only a few months of survival. This supports the paraphrase that some professionals doubt PM will significantly benefit all patients. (LLM, conf=0.88)
- Supportedcites [57] Beskow LM, Hammack CM, Brelsford KM. Thought leader perspectives on benefits and harms in precision medicine research. PLoS ONE. 2018;13(11):e0207842. source
In Results > Individual benefits, a thought leader says that a potentially life-saving result may not occur for everyone, ‘probably not even to most people.’ The Discussion likewise says that direct benefit from precision medicine research results would accrue to only a small fraction of participants. (LLM, conf=0.90)
boosted- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Professionals also describe a lack in their own knowledge or a limited understanding, as quantitative studies demonstrate [36, 37, 44, 81, 82, 92, 103, 104].”
§ Patients’ and professionals’ views related to ethical issues in precision medicine: a mixed research synthesis > Results > Professionals’ knowledge and competence
What the sources say
- Could not verifycites [36] Al Bakir I, Sebepos-Rogers GM, Burton H, Monahan KJ. Genomic medicine in gastroenterology, present and future: a nationwide survey of higher speciality trainees. Gut. 2018;67:A271-A. sourceExperimental — accuracy not yet measured
The Introduction and Discussion address dietary inulin-type fructans and endothelial dysfunction in mice, not professionals’ understanding of precision medicine. Searches for professionals’ knowledge, precision medicine, and related survey findings found no passage addressing the claim; page numbers were not available in our copy. (LLM, conf=0.78)
- Supportedcites [37] Al Bakir I, Sebepos-Rogers GM, Burton H, Monahan KJ. Mainstreaming of genomic medicine in gastroenterology, present and future: a nationwide survey of UK gastroenterology trainees. BMJ Open. 2019;9(10):e030505. source
The Results section reports that fewer than one-quarter of surveyed UK gastroenterology trainees felt they understood what mainstreaming genomic practice entails. The Discussion also describes respondents’ concern about their knowledge base. These findings support the claim for the professionals surveyed, rather than professionals generally. (LLM, conf=0.92)
- Supportedcites [44] Alexander KM, Divine HS, Hanna CR, Gokun Y, Freeman PR. Implementation of personalized medicine services in community pharmacies: perceptions of independent community pharmacists. J Am Pharm Assoc. 2014;54(5):510–7. source
The Results (page not provided) report that 38% of surveyed pharmacists had no existing knowledge of personalized medicine. The Discussion (page not provided) also reports that 55% felt they lacked knowledge about genetic polymorphisms, supporting the claim about professionals’ self-described knowledge gaps. (LLM, conf=0.93)
- Supportedcites [81] Obeng AO, Fei KZ, Levy KD, Elsey AR, Pollin TI, Ramirez AH, et al. Physician-reported benefits and barriers to clinical implementation of genomic medicine: a multi-site IGNITE-network survey. J Pers Med. 2018;8(3):13. source
The Discussion reports that physicians in this survey perceived their training as inadequate and lacked confidence using genomic information. Results §4.4 supports this with survey responses: only one third felt their training prepared them to work with genetically high-risk patients, and 15% felt confident using genetic results in practice. (LLM, conf=0.93)
- Supportedcites [82] Alharbi AA, Shaqran TM, Eltobgy AAE, Albalawi AR, Alnawmasi WS. Physicians’ perspective on diabetes mellitus management within the context of personalized medicine Era in Tabuk Governorate, Saudi Arabia. Open Access Maced J Med Sci. 2019;7(10):1706–11. source
The Abstract (Results) says that 82.54% of surveyed physicians expressed unsatisfactory knowledge of personalised diabetes management. The Results also report that 82.5% had a poor level of knowledge about its personalised-medicine elements, supporting the claim about limited understanding in this quantitative study. (LLM, conf=0.91)
- Not checked — no full text of the sourcecites [92] Scheuner MT, Sieverding P, Shekelle PG. Delivery of genomic medicine for common chronic adult diseases: a systematic review. JAMA. 2008;299(11):1320–34. source
- Not checked — no full text of the sourcecites [103] Petersen KE, Prows CA, Martin LJ, Maglo KN. Personalized medicine, availability, and group disparity: an inquiry into how physicians perceive and rate the elements and barriers of personalized medicine. Pub Health Genom. 2014;17(4):209–20. source
- Supportedcites [104] Vorderstrasse A, Katsanis SH, Minear MA, Yang N, Rakhra-Burris T, Reeves JW, et al. Perceptions of personalized medicine in an academic health system: educational findings. J Contemp Med Educ. 2015;3(1):14–9. source
The Abstract Results report that providers felt ill-equipped to implement personalized medicine. The Discussion says providers acknowledged a need for continuing education in personalized and precision medicine, supporting the claim as a description of their self-reported knowledge needs rather than an objective test of understanding. (LLM, conf=0.86)
boosted- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
Every source the paper cites for this claim was checked and supports it.
In the paper
“For example, in Saudi Arabia, where healthcare is predominantly taxpayer-funded [109], 27.8% of physicians surveyed (n = 126) doubted that patients would have easy access to PM [82].”
§ Patients’ and professionals’ views related to ethical issues in precision medicine: a mixed research synthesis > Results > Access to precision medicine
What the sources say
- Supportedcites [82] Alharbi AA, Shaqran TM, Eltobgy AAE, Albalawi AR, Alnawmasi WS. Physicians’ perspective on diabetes mellitus management within the context of personalized medicine Era in Tabuk Governorate, Saudi Arabia. Open Access Maced J Med Sci. 2019;7(10):1706–11. source
The Results (Table 3) report that 35 of 126 physicians (27.78%) had an unfavourable attitude toward 'Easy Patients’ Accessibility' to personalized diabetes medicine. Rounded to 27.8%, this supports the claim about the physicians surveyed in Tabuk, Saudi Arabia. (LLM, conf=0.94)
plainn = 126- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
55 more claims · 24 with their cited sources checked
Create a free account to see all 157 claims and to verify the 45 references still open.
- Probably not a substantial claim. 70
- It may state two separate claims as one. 46
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Patients’ and professionals’ views related to ethical issues in precision medicine: a mixed research synthesis > Results > Patients’ data provision and health-related work
“The willingness to participate in research and to provide genetic information, lifestyle, environmental or medical data was examined in a Korean study with 526 participants.”
§ Patients’ and professionals’ views related to ethical issues in precision medicine: a mixed research synthesis > Results > Access to precision medicine
“84.8% of the participants (n = 542) were concerned that this would increase disparity in public health [47].”
Citations
Cites
Principles of Biomedical Ethics
(2012) · Thieves of Virtue · doi:10.7551/mitpress/9079.003.0009 · Cited by 13,453
Principles of biomedical ethics
Horton, J. (2002) · Transactions of the Royal Society of Tropical Medicine and Hygiene · doi:10.1016/s0035-9203(02)90265-8 · Cited by 4,377
Frontiers of justice: disability, nationality, species membership
(2006) · Choice Reviews Online · doi:10.5860/choice.44-2056 · Cited by 3,802
Ashley, E. A. (2016) · Nature Reviews Genetics · doi:10.1038/nrg.2016.86 · Cited by 1,116
Healthcare Data Breaches: Insights and Implications
Seh, A. H., Zarour, M., Alenezi, M., Sarkar, A. K., Agrawal, A., Kumar, R., & Ahmad Khan, R. (2020) · Healthcare · doi:10.3390/healthcare8020133 · Cited by 600
(2006) · PubMed · Cited by 485
Delivery of Genomic Medicine for Common Chronic Adult Diseases: A Systematic Review
Scheuner, M. T., Sieverding, P., & Shekelle, P. G. (2008) · JAMA · doi:10.1001/jama.299.11.1320 · Cited by 305
Kraft, S. A., Cho, M. K., Gillespie, K., Halley, M., Varsava, N., Ormond, K. E., Luft, H. S., Wilfond, B. S., & Lee, S. S.-J. (2018) · The American Journal of Bioethics · doi:10.1080/15265161.2018.1431322 · Cited by 271 · cited 1×
“(2018) drew attention to the inability of US immigrants to navigate the healthcare system which can result in a lack of trust in the healthcare system [114].”
BackgroundCatry, E., Bindels, L. B., Tailleux, A., Lestavel, S., Neyrinck, A. M., Goossens, J.-F., Lobysheva, I., Plovier, H., Essaghir, A., Demoulin, J.-B., et al. (2018) · Gut · doi:10.1136/gutjnl-2016-313316 · Cited by 194
Attitudes of Patients With Cancer About Personalized Medicine and Somatic Genetic Testing
Gray, S. W., Hicks-Courant, K., Lathan, C. S., Garraway, L., Park, E. R., & Weeks, J. C. (2012) · Journal of Oncology Practice · doi:10.1200/jop.2012.000626 · Cited by 139 · cited 5×
“For example, professionals [45, 120], patients and representatives from patient organizations are concerned about whether health insurance companies will cover the costs [51, 63, 76] or patients can pay for them [61, 95, 96].”
BackgroundInfluential
Research works printed but not linked: 6
- Maio G. Chancen und Grenzen der personalisierten Medizin - eine ethische Betrachtung. Gesundheit und Gesellschaft - Wissenschaft. 2012;12(1):15–9.
- Sen A. The idea of justice. London: Penguin; 2010.
- Maio G. Mittelpunkt Mensch: Ethik in der Medizin. Frankfurt am Main: Schattauer; 2012.
- Miller AM, Garfield S, Woodman RC. Patient and provider readiness for personalized medicine. Pers Med Oncol. 2016;5(4):158–67.
- Sommer M, Nielsen MM, Vesteghem C, Bogsted M, Dybkjaer K, Johnsen HE, et al. Hämatological cancer patients’ position on precision medicine—a questionnaire survey. Basic Clin Pharmacol Toxicol. 2018;123:4.
- Kraft SA, Cho MK, Gillespie K. Beyond consent: building trusting relationships with diverse populations in precision medicine research. Am J Bioeth. 2018;18(4):3–20. · DOI · Paper page
Cited by
Exploring the gut microbiota: lifestyle choices, disease associations, and personal genomics
Matute, S. P., & Iyavoo, S. (2023) · Frontiers in Nutrition · doi:10.3389/fnut.2023.1225120 · Cited by 153
Precision oncology: transforming cancer care through personalized medicine
Rituraj, Pal, R. S., Wahlang, J., Pal, Y., Chaitanya, M., & Saxena, S. (2025) · Medical Oncology · doi:10.1007/s12032-025-02817-y · Cited by 74
Xu, S., Wang, Q., & Ma, W. (2024) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2024.02.003 · Cited by 55
Windolf, H., Chamberlain, R., & Quodbach, J. (2022) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2022.121555 · Cited by 40
Genetic/genomic testing: defining the parameters for ethical, legal and social implications (ELSI)
Ascencio-Carbajal, T., Zavala, G. S., Navarro‐García, F., & Frixione, E. (2021) · BMC Medical Ethics · doi:10.1186/s12910-021-00720-5 · Cited by 41
Metadata
- Authors
- Erdmann, A., Rehmann-Sutter, C., & Bozzaro, C.
- Affiliations
- Christian-Albrechts-Universität zu Kiel (DE)
- Corresponding author
- Erdmann, Anke
- Venue
- BMC Medical Ethics
- Published
- 2021-08-31
- Volume
- 22
- Issue
- 1
- Pages
- 116-116
- ISSN
- 1472-6939 (ISSN-L)
- PMC
- PMC8406914
- OpenAlex
- W3197057224
- Cited by
- 86
- References
- 130
- Citations by year
- 2026: 12 · 2025: 26 · 2024: 22 · 2023: 14 · 2022: 9 · 2021: 3
- FWCI
- 2.14
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- BMC Medical Ethics (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Multimedialen Archiv und Publikationsserver der Christian-Albrechts-Universität zu Kiel (Christian-Albrechts-Universität zu Kiel) (submittedVersion, cc-by)
- Funders
- Deutsche Forschungsgemeinschaft (F381 434.)
- Universitätsklinikum Schleswig-Holstein - Campus Kiel
- Topics
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Ethics and bioethics in healthcare
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Ethics in Clinical Research
- Social Sciences › Law › Medical and Health Sciences Research
- Keywords
- precision medicine, bioethics, patient attitudes, healthcare professionals' perspectives, informed consent, incidental finding, genetic discrimination, justice, autonomy, data security, physician-patient relationship, cost-effectiveness, genetic testing
- MeSH terms
- Artificial Intelligence, Humans, Informed Consent, Physician-Patient Relations, Quality of Life, Precision Medicine
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol and qwen3.8-omni-flash).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Patients’ and professionals’ views related to ethical issues in precision medicine: a mixed research synthesis. https://app.cochat.ai/papers/10.1186/s12910-021-00682-8
- The paper
- Erdmann, A., Rehmann-Sutter, C., & Bozzaro, C. (2021). Patients’ and professionals’ views related to ethical issues in precision medicine: a mixed research synthesis. BMC Medical Ethics. https://doi.org/10.1186/s12910-021-00682-8
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.

